Cargando…

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)

meta-iodobenzylguanidine (MIBG) radiolabelled with iodine-131 is used for diagnosis and treatment of neuroadrenergic neoplasms such as phaeochromocytoma and neuroblastoma. In addition, non-radiolabelled MIBG, administered i.v., is used in several clinical studies. These include palliation of the car...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuin, A, Rutgers, M, Valk, M A van der, Beijnen, J H, Smets, L A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362668/ https://www.ncbi.nlm.nih.gov/pubmed/10070872 http://dx.doi.org/10.1038/sj.bjc.6690128

Ejemplares similares

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG)
por: Kuin, A, et al.
Publicado: (1999)

A convenient Simple Method for Synthesis of Meta-iodobenzylguanidine (MIBG)
por: Sheikholislam, Zahra, et al.
Publicado: (2013)

Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake
por: Blom, Thomas, et al.
Publicado: (2020)

Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
por: Blom, Thomas, et al.
Publicado: (2021)

Reproducibility of planar (123)I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure
por: Veltman, Caroline E., et al.
Publicado: (2012)

Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999)

Impact of Diabetes on Cardiac Sympathetic Innervation in Patients With Heart Failure: A (123)I meta-iodobenzylguanidine ((123)I MIBG) scintigraphic study
por: Paolillo, Stefania, et al.
Publicado: (2013)

Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature.
por: Armour, A., et al.
Publicado: (1994)

Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats
por: Radwan, Mahasen A., et al.
Publicado: (2017)

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ((123/131)I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors
por: Grand-Guillaume, Joana, et al.
Publicado: (2023)

(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
por: Garaventa, A, et al.
Publicado: (1999)

131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
por: Gaze, M. N., et al.
Publicado: (1992)

Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy
por: Mastrangelo, S, et al.
Publicado: (2001)

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters
por: Kölby, L, et al.
Publicado: (2003)

OR03-01 Effects Of Alpha-emitting Meta-(211)At-astato-benzylguanidine ((211)At-MABG) Compared To (131)I-meta-iodobenzylguanidine ((131)I-MIBG) on Tumor Growth Suppression in a Pheochromocytoma Mouse Model
por: Yoshinaga, Keiichiro, et al.
Publicado: (2020)

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients
por: van Andel, L., et al.
Publicado: (2017)

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients
por: van Andel, L., et al.
Publicado: (2017)

Reduced inflammatory and muscle damage biomarkers following oral supplementation with bioavailable curcumin
por: McFarlin, Brian K., et al.
Publicado: (2016)

Cardiac (123)I-mIBG Imaging in Heart Failure
por: Verschure, Derk O., et al.
Publicado: (2022)

Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma
por: Jimenez, Camilo, et al.
Publicado: (2022)

Bioavailability of the flavonol quercetin in neonatal calves after oral administration of quercetin aglycone or rutin
por: Maciej, J., et al.
Publicado: (2015)

(123)I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases
por: Nakajima, Kenichi, et al.
Publicado: (2016)

A model of modified meta-iodobenzylguanidine conjugated gold nanoparticles for neuroblastoma treatment
por: Saimuang, Kween, et al.
Publicado: (2021)

Bioavailability of the Common Cold Medicines in Jellies for Oral Administration
por: Kim, Ki Hyun, et al.
Publicado: (2020)

Pharmacokinetic and Bioavailability Studies of Embelin after Intravenous and Oral Administration to Rats
por: Li, Zhen, et al.
Publicado: (2019)

Study on Pharmacokinetic and Bioavailability of Tamarixetin after Intravenous and Oral Administration to Rats
por: Shen, Jiayuan, et al.
Publicado: (2019)

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice
por: Oostendorp, Roos L., et al.
Publicado: (2010)

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Radiosynthesis of no-carrier-added meta-[(124)I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma
por: Green, Michael, et al.
Publicado: (2016)

P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo
por: van Tellingen, O, et al.
Publicado: (2003)

Sequelae and survivorship in patients treated with (131)I-MIBG therapy
por: Sze, W C C, et al.
Publicado: (2013)

Time-dependent simvastatin administration enhances doxorubicin toxicity in neuroblastoma
por: Anderson, Colin C., et al.
Publicado: (2020)

Comparative Bioavailability of Two Diosmin Formulations after Oral Administration to Healthy Volunteers
por: Russo, Rosario, et al.
Publicado: (2018)

Preclinical Pharmacokinetics and Bioavailability of Oxypeucedanin in Rats after Single Intravenous and Oral Administration
por: Zheng, Ming-Cong, et al.
Publicado: (2022)

The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro.
por: Armour, A., et al.
Publicado: (1997)

Biological Distribution of Orally Administered [(123)I]MIBG for Estimating Gastrointestinal Tract Absorption
por: Kobayashi, Masato, et al.
Publicado: (2021)

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
por: van Asperen, J., et al.
Publicado: (1997)

Nothing but NET: A review of norepinephrine transporter expression and efficacy of (131)I-mIBG therapy
por: Streby, Keri A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7lth6in8te56ak9tri9jrcu8r1